Hsp90? Polyclonal Antibody

Hsp90? Polyclonal Antibody

CAT N°: 25725
Price:

604.00 513.40

Heat shock protein 90 ? (Hsp90?) is the inducible cytosolic isoform of Hsp90 that is encoded by HSP90AA in humans.{17930} Hsp90 is a multidomain protein that functions as a molecular chaperone to assist in folding and activation of nascent peptides, refolding unfolded or misfolded proteins, and preventing protein aggregation.{15502} C-terminal dimerization of Hsp90, coupled with ATPase molecular clamp activity induces a conformational change in the N-terminal nucleotide binding domain that facilitates substrate binding and initiates the chaperone cycle.{17932} Hsp90 interacts with many co-chaperones during its chaperone cycle including p23 and Sba1, which help recruit substrates to the Hsp90 complex, Hsp70 (Item Nos. 22739 | 23002), which loads nascent polypeptides onto the Hsp90 dimer, and the ATPase activator Aha1 that promotes ATP hydrolysis and substrate release.{17931,41851} Hsp90 is overexpressed in cancer cells and stabilizes client proteins that promote oncogenesis, including transcription factors, signaling proteins, and kinases.{17930,41851} Hsp90 also decreases ?-synuclein fibril formation and toxicity as well as Q35 aggregation in in vitro models of Parkinson’s and Huntington’s disease, respectively, implying a role in neurodegenerative disease.{41852} Cayman’s Hsp90? Polyclonal Antibody can be used for Western blot and ELISA applications. This antibody recognizes Hsp90? at 85 kDa from human, mouse, and rat samples.

Territorial Availability: Available through Bertin Technologies only in France

  • Correlated keywords
    • anti-body Hsp-90-? Hsp-90? Hsp90-? AA 70 p-23 Sba-1 HSP86 86 70 LAP-2 LAP2 Renal carcinoma antigen NY-REN-38 NYREN38 REN38 Lipopolysaccharide HSP-90AA Q-35 Aha-1 HSP90AA1 HSP90A HSPC1 HSPCA
  • Product Overview:
    Heat shock protein 90 ? (Hsp90?) is the inducible cytosolic isoform of Hsp90 that is encoded by HSP90AA in humans.{17930} Hsp90 is a multidomain protein that functions as a molecular chaperone to assist in folding and activation of nascent peptides, refolding unfolded or misfolded proteins, and preventing protein aggregation.{15502} C-terminal dimerization of Hsp90, coupled with ATPase molecular clamp activity induces a conformational change in the N-terminal nucleotide binding domain that facilitates substrate binding and initiates the chaperone cycle.{17932} Hsp90 interacts with many co-chaperones during its chaperone cycle including p23 and Sba1, which help recruit substrates to the Hsp90 complex, Hsp70 (Item Nos. 22739 | 23002), which loads nascent polypeptides onto the Hsp90 dimer, and the ATPase activator Aha1 that promotes ATP hydrolysis and substrate release.{17931,41851} Hsp90 is overexpressed in cancer cells and stabilizes client proteins that promote oncogenesis, including transcription factors, signaling proteins, and kinases.{17930,41851} Hsp90 also decreases ?-synuclein fibril formation and toxicity as well as Q35 aggregation in in vitro models of Parkinson’s and Huntington’s disease, respectively, implying a role in neurodegenerative disease.{41852} Cayman’s Hsp90? Polyclonal Antibody can be used for Western blot and ELISA applications. This antibody recognizes Hsp90? at 85 kDa from human, mouse, and rat samples.

We also advise you